MATINAS BIOPHARMA HOLDINGS, INC. Debt Securities, Available-for-sale, Unrealized Loss
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Debt Securities, Available-for-sale, Unrealized Loss of $523.25 thousand for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2020-05-11
- MATINAS BIOPHARMA HOLDINGS, INC. debt securities, available-for-sale, unrealized loss for the quarter ending 2020-03-31 was $523.25K.
- MATINAS BIOPHARMA HOLDINGS, INC. debt securities, available-for-sale, unrealized loss for fiscal 2019 was $880.00.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|---|
| 2020-03-31 | $523.25K 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $880.00 10-K · filed 2020-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |